Yesterday, the EVP, Chief Legal & Compliance of Tandem Diabetes Care Inc (TNDM), David B. Berger, bought shares of TNDM for $5,180.
Following this transaction David B. Berger’s holding in the company was increased by 56.96% to a total of $242.8K. Following David B. Berger’s last TNDM Buy transaction on August 06, 2019, the stock climbed by 6.7%.
See today’s analyst top recommended stocks >>
Based on Tandem Diabetes Care Inc’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $93.26 million and GAAP net loss of $1.51 million. In comparison, last year the company earned revenue of $34.13 million and had a GAAP net loss of $59.36 million. The company has a one-year high of $74.81 and a one-year low of $26.40. The Company has a Price to Book ratio of 27.8786.
Starting in November 2018, TNDM received 21 Buy ratings in a row.
In the last 30 days, insiders have sold $7.8M worth of TNDM shares and purchased $143.5K worth of TNDM shares. The insider sentiment on Tandem Diabetes Care Inc has been neutral according to 54 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
David B. Berger’s trades have generated a 54.3% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.